<DOC>
	<DOCNO>NCT01205828</DOCNO>
	<brief_summary>This study people liver cancer ( also call hepatocellular carcinoma , HCC abbreviation ) . The purpose study test efficacy ( effectiveness ) new combination drug , ABT-888 temozolomide patient liver cancer . Temozolomide act damage deoxyribonucleic acid ( DNA ) rapidly divide cell , word , cancer cell . ABT-888 inhibits enzyme call `` PARP '' help fix damage DNA . By inhibit enzyme , ABT-888 prevents cancer cell repair damage cause temozolomide hopefully increase kill cancer cell , decrease tumor body . ABT-888 investigational experimental anti-cancer agent yet approve Food Drug Administration ( FDA ) use liver cancer . This study help find effect ( good bad ) combination drug , temozolomide ABT-888 , liver cancer . This research do know ABT-888 increase effectiveness temozolomide liver cancer .</brief_summary>
	<brief_title>ABT-888 Temozolomide Liver Cancer</brief_title>
	<detailed_description>Patients hepatocellular carcinoma see Lombardi Cancer Center evaluate eligibility study . The Georgetown Lombardi Comprehensive Cancer Center responsible data safety monitoring trial . As study investigator initiate study Phase II study utilize non-FDA approved drug PI hold IND consider high risk study real-time monitoring PI study team quarterly review LCCC Data Safety Monitoring Committee ( DSMC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Pathological confirmation HCC noninvasive criterion follow AASLD guideline Measurable evaluable disease base RECIST criterion Progressive disease sorafenib intolerance sorafenib ECOG performance status 02 Child Pugh Class A B Adequate hepatic , bone marrow , renal function Prior ABT888 PARP inhibitor treatment Anticipation need major surgery study Any follow within 6 month enrollment : myocardial infarction , severe/unstable angina , congestive heart failure , severe pulmonary disease Women pregnant lactate Women men childbearing potential use reliable form contraception History allergic reaction attribute compound similar chemical biologic composition ABT888 temozolomide Concurrent malignancy ( i.e . malignancy hepatocellular cancer ) unless 1 ) subject curatively treat disease free least 2 year 2 ) cancer nonmelanoma skin cancer early cervical cancer . Uncontrolled intercurrent illness include , limited , ongoing active infection ( exclude active hepatitis B C ) psychiatric illness/ social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>hepatocellular</keyword>
	<keyword>temozolomide</keyword>
	<keyword>veliparib</keyword>
</DOC>